Urodilatin
Urodilatin is an analogue of ANF-(99-126). Urodilatin is a diuretic-natriuretic regulatory peptide. Urodilatin can be used for research of acute renal failure, congestive heart failure, and bronchial asthma, etc.
For research use only. We do not sell to patients.
- CAS No.: 115966-23-9
- Formula: C145H236N52O44S3
- Molecular Weight:3507.94
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
-
HY-B2130A
Uric acid sodiumOxygen Radical Scavenger -
HY-B2130AR
Uric acid sodium (Standard)Reference Standard -
HY-90009S
Tadalafil-d3Stable Isotope -
HY-B0209S
Metolazone-d7Stable Isotope -
HY-13955S
Telmisartan-d3Stable Isotope -
HY-100796
GuanoclorAntihypertensive Agent -
HY-B0193S
Prazosin-d8Stable Isotope -
HY-134043
Chlorthalidone Impurity G -
HY-W011240S
Hydroflumethiazide-13C,d2Stable Isotope -
HY-B0309S1
Felodipine-d5Stable Isotope -
HY-129511
Conivaptan-d4Stable Isotope
Biological Activity
Description
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 115966-23-9
-
Molecular Weight 3507.94
-
Formula C145H236N52O44S3
-
Sequence
Thr-Ala-Pro-Arg-Ser-Leu-Arg-Arg-Ser-Ser-Cys-Phe-Gly-Gly-Arg-Met-Asp-Arg-Ile-Gly-Ala-Gln-Ser-Gly-Leu-Gly-Cys-Asn-Ser-Phe-Arg-Tyr
-
Sequence Shortening
TAPRSLRRSSCFGGRMDRIGAQSGLGCNSFRY
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Research Protocol for Cardiovascular Diseases
Cardiovascular disease can be modeled as maladaptive cardiac remodeling, where ischemic injury or pressure overload activates inflammatory signaling, fibroblast activation, extracellular-matrix deposition, cardiomyocyte hypertrophy, vascular remodeling, and progressive ventricular dysfunction. The TGF-β/SMAD axis is a central profibrotic pathway after myocardial injury and pressure overload, while innate immune and cytokine pathways regulate leukocyte recruitment, scar formation, and adverse remodeling. Key unresolved questions include which inflammatory signals are reparative versus harmful, when fibrosis is protective versus maladaptive, and whether pathway inhibition improves function without weakening necessary infarct healing or compensatory remodeling.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Urodilatin Related Classifications
HY-120521 Related Classifications
Powered by Bioz